Nuvectis Pharma, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Nuvectis Pharma, Inc. (NVCT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$9.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-04
- Nuvectis Pharma, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$6.50M, a 157.40% decline year-over-year.
- Nuvectis Pharma, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $11.33M, a 3252.37% increase year-over-year.
- Nuvectis Pharma, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $338.00K.
- Nuvectis Pharma, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$4.53M, a 141.32% decline year-over-year.
- Nuvectis Pharma, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $13.10M.
- Nuvectis Pharma, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$593.00K.
- Nuvectis Pharma, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$867.00K, a 106.08% decline from fiscal 2022.
- Nuvectis Pharma, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $14.25M, a 148.19% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.47M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | -$6.50M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $13.10M 10-K · filed 2026-02-11 | |||
| 2025-09-30 | $16.91M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $8.26M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | $11.33M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$593.00K 10-K · filed 2026-02-11 | |||
| 2024-09-30 | -$1.96M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$1.01M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $338.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | -$867.00K 10-K · filed 2025-02-25 | |||
| 2023-09-30 | $2.07M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | $4.61M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$4.53M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $14.25M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | $17.90M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $7.83M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $10.95M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $5.74M 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $6.81M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $7.21M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |